Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$368.42 USD

368.42
284,333

+10.23 (2.86%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails

Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.

Myriad Genetics (MYGN) Makes Progress in Precision Oncology

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Here's Why You Should Retain Abbott (ABT) Stock for Now

Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.

Walgreens (WBA), Village MD Plan to Expand Into New Hampshire

Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.

Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.

Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Cardiovascular Systems (CSII) Finances New DCB Development

Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.

Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise

Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.

Bio-Rad (BIO) Loses 15.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bio-Rad (BIO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why You Should Retain Charles River (CRL) Stock For Now

Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.

Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?

Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes

Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.

Thermo Fisher (TMO) Extends Collaboration With Symphogen

Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.

Medtronic (MDT) Gains Market Share Despite COVID Headwinds

In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.

Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat

Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.

Patterson Companies (PDCO) Q3 Earnings Beat, Revenues Lag

Patterson Companies' (PDCO) fiscal third-quarter 2022 results benefit from strength in the Dental and Animal Health segments.

Insulet (PODD) Product Volume Up, COVID-Led Softness Persists

Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.

Henry Schein (HSIC) Expands Data Analytics to Private Practices

Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.